Patent classifications
A61K35/02
Therapeutic clay compositions and methods of using
The present invention provides methods of improve efficiency, growth, and performance in an animal by orally administering to the animal an effective amount of a therapeutic clay. The methods can reduce embryonic loss, increase litter size, increase the number of live births, improve the immune status of the maternal animal, reduce the concentration of maternal fecal amino acids, reduce the concentration of maternal fecal short-chained amino acid, increasing litter birth weight in the maternal animal, increase the amount of young animal colostrum intake, reduce young animal pre-weaning mortality, reduce the number of young animals lost due to low viability, reduce the number of weaned young animals, improve the immune status of young animals at weaning, reduce the number of lightweight young animals from nursery to market, increase the number of young animals marketed per sow, and increase calculated litter weight gain.
Therapeutic clay compositions and methods of using
The present invention provides methods of improve efficiency, growth, and performance in an animal by orally administering to the animal an effective amount of a therapeutic clay. The methods can reduce embryonic loss, increase litter size, increase the number of live births, improve the immune status of the maternal animal, reduce the concentration of maternal fecal amino acids, reduce the concentration of maternal fecal short-chained amino acid, increasing litter birth weight in the maternal animal, increase the amount of young animal colostrum intake, reduce young animal pre-weaning mortality, reduce the number of young animals lost due to low viability, reduce the number of weaned young animals, improve the immune status of young animals at weaning, reduce the number of lightweight young animals from nursery to market, increase the number of young animals marketed per sow, and increase calculated litter weight gain.
METHOD FOR TREATING PSORIASIS
The present invention relates to a method for treating psoriasis including: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Pimenta officinalis, Paeonia veitchii, Anastatica hierochuntica, Zingiber officinale, Scutellaria baicalensis, and Ziziphus jujube.
METHOD FOR TREATING PSORIASIS
The present invention relates to a method for treating psoriasis including: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Pimenta officinalis, Paeonia veitchii, Anastatica hierochuntica, Zingiber officinale, Scutellaria baicalensis, and Ziziphus jujube.
CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE
Feed additive compositions and methods of using the additives to improve the performance of an adult animal are disclosed. Improved performance can include reducing maintenance nutrient requirements, improving growth performance, reducing the energy required for intestinal maintenance, reducing the energy required for weight gain, reduced morbidity, increasing growth rate, improving feed conversion, improving the average daily gain (ADG), improving the efficiency of nutrient utilization, increasing volatile fatty acid production, improving energy use from volatile fatty acids, increasing ending body weight, improved intestinal health, increased relative abundance of Bifidobacterium in the intestines, or combinations thereof.
CLAY COMPOSITIONS AND METHODS FOR IMPROVING ANIMAL PERFORMANCE
Feed additive compositions and methods of using the additives to improve the performance of an adult animal are disclosed. Improved performance can include reducing maintenance nutrient requirements, improving growth performance, reducing the energy required for intestinal maintenance, reducing the energy required for weight gain, reduced morbidity, increasing growth rate, improving feed conversion, improving the average daily gain (ADG), improving the efficiency of nutrient utilization, increasing volatile fatty acid production, improving energy use from volatile fatty acids, increasing ending body weight, improved intestinal health, increased relative abundance of Bifidobacterium in the intestines, or combinations thereof.
NON-LETHAL DEFENSIVE FLUID COMPOSITION AND PRESSURIZED DELIVERY SYSTEM
A lubric gel composition for personal defense includes a fatty acid at a concentration ranging from 5 wt % to 10 wt % of the composition, a thickening agent at a concentration ranging from 1.75 wt % to 8.75 wt % of the composition, a detergent at a concentration ranging from 1.03 wt % to 4.07 wt % of the composition, a surfactant at a concentration ranging from 2 wt % to 15 wt % of the composition, and water at a concentration ranging from 66 wt % to 90.21 wt % of the composition.
NON-LETHAL DEFENSIVE FLUID COMPOSITION AND PRESSURIZED DELIVERY SYSTEM
A lubric gel composition for personal defense includes a fatty acid at a concentration ranging from 5 wt % to 10 wt % of the composition, a thickening agent at a concentration ranging from 1.75 wt % to 8.75 wt % of the composition, a detergent at a concentration ranging from 1.03 wt % to 4.07 wt % of the composition, a surfactant at a concentration ranging from 2 wt % to 15 wt % of the composition, and water at a concentration ranging from 66 wt % to 90.21 wt % of the composition.
Maillard reaction products as inhibitors of aggregatibacter actinomycetemcomitans
Maillard reaction products produced by heating carbohydrates with one or more amino acids (e.g., lysine), at basic pH and for a selected reaction time at a particular concentration in solution, can exhibit inhibitory activity against Aggregatibacter actinomycetemcomitans.
Maillard reaction products as inhibitors of aggregatibacter actinomycetemcomitans
Maillard reaction products produced by heating carbohydrates with one or more amino acids (e.g., lysine), at basic pH and for a selected reaction time at a particular concentration in solution, can exhibit inhibitory activity against Aggregatibacter actinomycetemcomitans.